Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: KínaKorai 1. fázis

Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of Arnovie101, an mRNA-LNP-Based In Vivo CAR-T Therapy, for the Treatment of B Cell-Mediated Autoimmune Diseases (SLE and AIHA)

A legfontosabb adatok

Ki végzi
Circunited BioPharma (Shenzhen) Co., Ltd.
Hol
Beijing (Kína)A helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
Korai 1. fázis
Résztvevők
5 fő, tervezett
Kezdés
2026. ápr. 7.
Várható befejezés
2027. máj. 30.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Arnovie101 Infusion Intravenous
A regiszteradat frissítve
2026. június 5.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

A vizsgálat 18 és 60 év közötti felnőtteket keres, akiknek lupuszuk (SLE) vagy autoimmun hemolitikus anémiájuk (AIHA) kiújult, vagy a korábbi kezelésekre nem reagált.

Életkor
18 és 60 év között
Nem
Mindkét nem jelentkezhet.
A betegség stádiuma
SLE: legalább 6 hónapja fennálló, kiújuló vagy nehezen kezelhető betegség, a szűréskor 6 vagy annál magasabb SLEDAI-2K pontszámmal. AIHA vagy Evans-szindróma: legalább 3 kezelési vonal sikertelen volt, a hemoglobin 10 g/dL alatti, és vérszegénységi tünetek vannak.
Korábbi kezelés
SLE: gyenge válasz legalább két első vonalbeli kezelésre (szteroidokra és immunszuppresszánsokra), legalább két immunszuppresszáns használata, köztük hidroxiklorokin; legalább 8 hete stabil kezelés. AIHA: a szteroid, a rituximab és legalább egy harmadik vonalbeli kezelés (például lépeltávolítás vagy ciklosporin) sikertelen volt.

A részvétel fő kizáró okai

  • Terhes vagy szoptató nők
  • Aktív fertőzés, HIV vagy aktív hepatitis B vagy C
  • Korábbi CAR-T kezelés, szerv- vagy őssejt-átültetés
  • Súlyos idegrendszeri betegség, az SLE súlyos agyi érintettségét is beleértve
  • Közelmúltbeli szívbetegség, vagy daganatos betegség az elmúlt 5 évben (néhány bőr- és korai daganat kivételével)

A regiszter feltételei, szó szerint

Mind a 26 feltétel megnézéseKevesebb

Ki vehet részt

  • Ability to voluntarily sign informed consent, including compliance with the requirements and restrictions listed in the Informed Consent Form (ICF) and this protocol
  • Male or female, aged 18 to 60 years (inclusive) at screening
  • Participants with relapsed/refractory SLE with at least 6 months of disease history and meeting the following criteria:; Confirmed diagnosis of SLE according to the 2012 SLICC or 2019 EULAR/ACR revised criteria. SLEDAI-2K score ≥6 at screening. If the score includes low complement and/or anti-dsDNA antibodies, the clinical symptom score of SLEDAI-2K (excluding low complement and/or anti-dsDNA antibodies) should be ≥4. Poor response to standard therapy (at least two first-line treatments, including corticosteroids and immunosuppressants) and disease relapse after treatment; SLE: Stable standard therapy (including non-steroidal anti-inflammatory drugs, immunosuppressants, biologics, and glucocorticoids; oral glucocorticoid dose of prednisone or equivalent ≥7.5 mg/day and ≤30 mg/day; if combined with an immunosuppressant, no minimum daily dose requirement) for at least 8 weeks before screening, with current dose stable for at least 2 weeks and expected to remain stable during the study. Prior use of at least two immunosuppressants including hydroxychloroquine; Life expectancy >6 months
  • Participants with AIHA meeting the following criteria:; Participants with AIHA or Evans syndrome who have failed ≥3 lines of therapy; Failure of ≥3 lines of therapy must meet all of the following: hemoglobin <10 g/dL with symptoms of anemia; failure of first-line corticosteroid therapy; failure of second-line rituximab therapy; failure of any one or more third-line regimens (splenectomy, cyclosporine, cyclophosphamide, azathioprine, mycophenolate mofetil, fludarabine, bortezomib, etc.); Life expectancy >3 months
  • Adequate organ function:; Renal function: Calculated creatinine clearance (Cockcroft-Gault) ≥30 mL/min without hydration support; Bone marrow function: Absolute neutrophil count (ANC) ≥1.0×10⁹/L, absolute lymphocyte count (ALC) ≥0.1×10⁹/L, hemoglobin (Hb) ≥60 g/L, platelet count (PLT) ≥20×10⁹/L. Coagulation: International normalized ratio (INR) or activated partial thromboplastin time (APTT) ≤1.5×ULN. Note: No blood transfusion, white blood cell growth factors (e.g., colony-stimulating factors), erythropoietin, or thrombopoietin within 7 days before the laboratory assessment; Hepatic function: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN, total bilirubin <2.0 mg/dL (for participants with Gilbert's syndrome, total bilirubin <3.0 mg/dL; except when caused by SLE itself); Pulmonary function: Dyspnea ≤CTCAE grade 1 and oxygen saturation (SpO₂) ≥92% on room air (measured by pulse oximeter)
  • Female participants must meet the following criteria: 1) Not pregnant or breastfeeding; 2) Surgically sterile or postmenopausal for ≥2 years, or if of childbearing potential (including those postmenopausal <2 years), have a negative serum pregnancy test (β-hCG) and agree to use effective contraception (e.g., condom, spermicide, or intrauterine device) during the study and for at least 12 months after the last dose. Use of progesterone-only contraceptives is not permitted; 3) Agree not to breastfeed during the study and for at least 12 months after the last dose
  • Male participants must meet the following criteria: If not surgically sterile and engaging in sexual activity that could lead to pregnancy, agree to use effective contraception (e.g., condom, spermicide) during the study and for at least 12 months after the last dose, and refrain from donating semen or sperm during the study and for 12 months after the last dose

Ki nem vehet részt

  • Presence of known active infection at screening, including active tuberculosis, active or infectious pneumonia, or recurrent peptic ulcer; requiring hospitalization, intravenous antibiotics within 4 weeks before screening, or oral antibiotics within 2 weeks before screening; history of herpes zoster within 12 weeks before screening; history of human immunodeficiency virus (HIV) or positive HIV antibody test; positive hepatitis B surface antigen (HBsAg) and/or positive anti-hepatitis B core antibody (HBcAb) with detectable hepatitis B virus (HBV) DNA above the lower limit of detection; positive hepatitis C virus (HCV) antibody with detectable HCV RNA above the lower limit of detection; positive syphilis antibody with active infection
  • Previous treatment with B-cell targeted therapies such as belimumab, rituximab, telitacicept; anti-CD22 agents (e.g., epratuzumab); anti-CD52 agents (e.g., alemtuzumab), or other similar biologics; TNF-α antagonists, IL-6 antagonists, IL-1 antagonists, selective T-cell costimulation modulators, etc., with less than 5 half-lives before screening
  • Use of any other investigational drug for SLE in a clinical trial within 4 weeks before screening
  • Receipt of non-biologic investigational drugs (e.g., BTK inhibitors, JAK inhibitors), intravenous immunoglobulin, or plasma exchange within 4 weeks or 5 half-lives (whichever is shorter) before screening
  • Vaccination within 30 days before the first dose of study drug
  • Prior treatment with mRNA-LNP or other LNP-based drugs within 2 years before the first dose of study drug
  • Prior CAR-T cell therapy
  • Major surgery within 4 weeks before the first dose of study drug, or minor surgery within 2 weeks before the first dose
  • History of active severe or unstable neuropsychiatric SLE, including but not limited to poorly controlled seizures, psychosis, acute confusional state, cerebrovascular accident, demyelinating syndrome, cranial neuropathy, or active central nervous system vasculitis
  • Presence of clinically significant central nervous system disease or pathology before screening, including but not limited to: cerebrovascular accident, aneurysm, epilepsy, convulsions/seizures, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis
  • History of major organ transplantation (e.g., heart, lung, kidney, liver) or hematopoietic stem cell/bone marrow transplantation
  • Malignancy within 5 years before signing the ICF, except for: curatively treated basal cell carcinoma of the skin, superficial bladder cancer, localized prostate cancer, biopsy-proven cervical carcinoma in situ or cervical squamous intraepithelial lesion detected by Pap smear, and completely resected ductal carcinoma in situ of the breast
  • Presence of other serious diseases, including liver disease, neurological/psychiatric disorders, endocrine system disorders, hematological disorders (including moderate-to-severe dyslipidemia and related conditions), which in the investigator's judgment would affect participation in this study
  • History of asthma, severe allergic reactions, or known allergy to any active or inactive ingredient of the study drug (including background therapy)
  • Severe mental disorder or suicidal tendency
  • Any other condition that, in the investigator's judgment, makes the participant unsuitable for this study
  • History of any of the following cardiovascular diseases within 6 months before screening: New York Heart Association (NYHA) class II or higher heart failure, myocardial infarction, unstable angina, uncontrolled or symptomatic atrial arrhythmias (e.g., second-degree type II atrioventricular block, third-degree atrioventricular block, symptomatic bradycardia with ventricular rate <50 bpm), any ventricular arrhythmia, or other clinically significant heart disease. QTcF >480 ms (Fridericia's formula), left ventricular ejection fraction (LVEF) <50% by echocardiography at screening, or other significant electrocardiogram abnormalities
  • Presence of an unresected thymoma
  • Pregnant or lactating women

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 60 év között vagy?

Helyszínek itt: Kína

  • Beijing Gobroad Boren HospitalBeijing, KínaContact: Yajing Zhang, M.D.Résztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is an open lable and single arm study designed to evaluate the safety, PK and PD of Arnovie101 in B cell-mediated Autoimmune Disease

A vizsgálat csoportja

  • Arnovie101 treatment groupA vizsgált kezelés

    Participants will receive Arnovie101 infusion (a nanobody-modified LNP encapsulating mRNA for in vivo CAR-T therapy) at the specified dose level and on the specified study days.

    Kezelés: Arnovie101 Infusion Intravenous

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of Arnovie101, an mRNA-LNP-Based In Vivo CAR-T Therapy, for the Treatment of B Cell-Mediated Autoimmune Diseases (Systemic Lupus Erythematosus and Autoimmune Hemolytic Anemia)
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 13.
Illeszkedési kérdések
Forrás: NCT07629596: ki vehet részt
A regiszteradat frissítve
2026. június 5.